PUBLISHER: The Business Research Company | PRODUCT CODE: 1751020
PUBLISHER: The Business Research Company | PRODUCT CODE: 1751020
Human organoids are powerful models for studying human biology, disease mechanisms, and testing drug responses in ways that mimic real human organs. The main types of human organoids, such as brain, heart, intestinal, kidney, liver, lung, and pancreatic organoids, allow researchers to investigate specific organ-related diseases and conditions.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
Brain organoids, for instance, are used in drug discovery, neurology studies, infectious disease research, oncology research, and personalized medicine. These organoids are created using cutting-edge technologies, such as 3D bioprinting, hydrogels, scaffold-based methods, and magnetic levitation, which help replicate the three-dimensional structure and function of human tissues. The primary users of these organoids include pharmaceutical and biotechnology companies, contract research organizations (CROs), and academic research institutions, which use these models for various applications ranging from disease modeling to drug testing and personalized therapeutic development.
The human organoids market research report is one of a series of new reports from The Business Research Company that provides human organoids market statistics, including human organoids industry global market size, regional shares, competitors with a human organoids market share, detailed human organoids market segments, market trends and opportunities, and any further data you may need to thrive in the human organoids industry. This human organoids market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The human organoids market size has grown rapidly in recent years. It will grow from $1.47 billion in 2024 to $1.71 billion in 2025 at a compound annual growth rate (CAGR) of 16.8%. The growth during the historic period can be attributed to a greater emphasis on personalized medicine, the rising prevalence of chronic diseases, advancements in regenerative medicine, the expansion of drug discovery applications, and the increase in government and private sector funding.
The human organoids market size is expected to see rapid growth in the next few years. It will grow to $3.15 billion in 2029 at a compound annual growth rate (CAGR) of 16.5%. The growth during the forecast period can be attributed to the rising demand for organoid-based disease modeling, increased investment in biotech research, expanding uses in drug screening, greater adoption in toxicology studies, and growing interest in precision medicine. Key trends in the forecast period include the integration of artificial intelligence, the development of patient-specific organoids, expansion into gene therapy applications, advancements in organoid bioprinting, and technological progress in 3D cell culture.
The growing number of genetic research experiments is expected to drive the growth of the human organoids market. Genetic science, which focuses on how traits are inherited through genes and how genetic information influences the development and functioning of organisms, is seeing an increase in experiments due to technological advancements that make gene editing faster and more accurate. These breakthroughs enable deeper research into diseases and the development of targeted treatments. In the context of human organoids, genetic science allows for precise manipulation of genes to model specific diseases and study their progression. This helps researchers better understand genetic disorders, test new drugs, and explore personalized treatment strategies. For example, in April 2023, a report by the National Institutes of Health (NIH), a US-based medical research agency, noted that by November 2022, the U.S. had registered 129,624 genetic tests, accounting for approximately 66% of all tests in the worldwide Genetic Testing Registry (GTR). As such, the rising number of genetic research experiments will contribute to the growth of the human organoids market.
Leading companies in the human organoids market are focusing on developing advanced stem cell technologies, such as next-generation 3D tissue culture platforms, to enhance the physiological relevance of in vitro models. A next-generation 3D tissue culture platform is an advanced in vitro system designed to more accurately replicate the complexity of human tissues compared to traditional 2D or earlier 3D models. For instance, in October 2022, AIM Biotech Pte. Ltd., a Singapore-based developer of tissue culture chips, introduced organiX, an advanced 3D tissue culture system. This system is designed to more accurately replicate human disease conditions by integrating organoids, functional vasculature, and immune cell components. The platform is tailored for cutting-edge drug development and personalized medicine, accommodating various tissue formats, such as organoids and tumor samples, within a controllable and physiologically relevant environment. It supports immune co-culture, allows real-time high-resolution imaging, and facilitates easy tissue retrieval for downstream analyses.
In January 2025, Merck Group, a Germany-based pharmaceutical company, acquired HUB Organoids Holding B.V. for an undisclosed amount. This acquisition aims to bolster Merck's next-generation biology portfolio by incorporating advanced organoid technology. This will accelerate drug development, provide deeper insights into treatments across various populations, and reduce the need for animal testing, aligning with Merck's commitment to innovative and ethical life sciences solutions. HUB Organoids Holding B.V., based in the Netherlands, specializes in human organoid research and applications.
Major players in the human organoids market are Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Corning Incorporated, Bio-Techne Corporation, Organovo Holdings Inc., Emulate Inc., MIMETAS B.V., Cellink AB, InSphero AG, Kerafast Inc., DefiniGEN Limited, Visikol Inc., CN Bio Innovations Limited, Cannex Scientific Inc., HeartBeat.bio AG, Kirkstall Ltd., Cyprio Ltd., 3Dnamics Inc., BrainZell Ltd., AIVITA Biomedical Inc.
North America was the largest region in the human organoids market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in human organoids report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the human organoids market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The human organoids market include revenues earned by entities by providing services such as drug discovery and development, disease modeling, toxicology testing, regenerative medicine research, and biomarker discovery. The market value includes the value of related goods sold by the service provider or included within the service offering. The human organoids market also consists of sales of products including organoid-based therapeutics, disease modeling solutions, drug testing platforms, and research applications. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Human Organoids Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on human organoids market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for human organoids ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The human organoids market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.